Time-course analysis of cisplatin induced AKI in preclinical models: implications for testing different sources of MSCs.

Abantika GangulyShashank ChettyRosita PrimaveraSteven LevitteShobha RegmiBenjamin William DulkenScott M SutherlandWendy AngelesJing WangAvnesh Sinh Thakor

Published in: Journal of translational medicine (2024)

Overall, our data underscores the importance of using an optimized preclinical model of cisplatin-AKI to test different therapies. We identified CXCL1 as a potential biomarker of cisplatin-AKI and identified the superior efficacy of UC-MSCs in mitigating cisplatin-AKI.

Keyphrases

acute kidney injury
mesenchymal stem cells
cell therapy
electronic health record
drinking water
stem cells
bone marrow